GSK Investigational Site

Shatin, New Territories

0 studies enrolling now · 11 studies all time

What they study most

Acute Coronary Syndrome, Atherosclerosis, Crohn's Disease, Myelodysplastic Syndrome, Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting, Purpura, Thrombocytopaenic, Idiopathic

Studies at this site

• An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease — Stopped early
• Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) — Completed
• Open-Label Extension Study of GSK1605786A — Stopped early
• GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease — Stopped early
• The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial — Completed
• A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60) — Completed
• LENS - Long-term Eltrombopag Observational Study — Completed
• Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women — Completed
• Post-Operative Nausea And Vomiting Study In Female Patients — Completed
• Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women — Completed
• A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) — Completed